Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Life Biosciences Inc.
Headquarters: Boston, MA, United States of America
Website: https://lifebiosciences.com
Year Founded: 2017
Status: Private
BioCentury | Jan 28, 2025
Management Tracks
Thomas Barnes named CEO of Averna
Plus: Panetta given emeritus title at Biocom and updates from Kailera, Harness, Nuevocor, Janux, Umoja and more
BioCentury | May 23, 2023
Management Tracks
Obsidian fills CEO, CDO roles with Iovance vets
Plus: Jami Rubin joins Arch, and updates from Exo, Harbinger, Twist and more
BioCentury | Feb 14, 2023
Management Tracks
J&J hires Sanofi’s Reed
Plus: Roth named COO at Zentalis and updates from Treeline, SpyBiotech and Life
BioCentury | Dec 24, 2022
BioCentury Commentary
Noisemakers and newsmakers of 2022, and hot takes for 2023
BioCentury’s analysts look back at a year when industry took some slings and arrows but delivered breakthroughs, and predict what’ll be hot in 2023
BioCentury | Feb 10, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into neurology
Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
BioCentury | Jan 7, 2022
Deals
Jan. 6 Quick Takes: Nextech leads $85M A round for molecular glue newco Ambagon
Plus: Odyssey builds out tool kit and updates from Amgen-Generate, Verily-Sosei, TRexBio-Janssen, Sutro, Sanofi and more
BioCentury | Oct 23, 2021
Product Development
Gene therapy’s next class of biotechs
And the innovative technologies they’re developing
BioCentury | Jul 8, 2021
Management Tracks
Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more
Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
BioCentury | Jun 5, 2021
Distillery Therapeutics
Small molecule activator of chaperone-mediated autophagy for Alzheimer’s
DISEASE CATEGORY: Neurology
INDICATION: Alzheimer’s disease A phenylacetamide-based compound that activates chaperone-mediated autophagy could treat Alzheimer’s disease. An expression
INDICATION: Alzheimer’s disease A phenylacetamide-based compound that activates chaperone-mediated autophagy could treat Alzheimer’s disease. An expression
BioCentury | Feb 3, 2021
Management Tracks
Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital
China-based in-licensing company AffaMed Therapeutics (Shanghai) Co. Ltd. hired Ji Li as president. Li was most recently a venture partner at Lilly Asia Ventures, and prior to that
Items per page:
1 - 10 of 15